New data from a 2024 meta-analysis provides precise measurements of magnesium’s blood pressure-lowering effects. Daily supplementation of 400 mg or higher, maintained for at least 12 weeks, reduces systolic blood pressure by 6.38 mmHg and diastolic pressure by 3.71 mmHg.
These reductions are most pronounced in patients with pre-existing metabolic disorders and documented magnesium deficiency, suggesting that baseline nutritional status influences treatment response. The magnitude of effect, while modest compared to pharmacological interventions, represents a clinically relevant contribution to overall cardiovascular risk reduction.
Magnesium exerts its benefits through endothelial stabilization and promotion of vasodilatory pathways. The findings support magnesium assessment as part of comprehensive hypertension management, particularly in populations with concurrent metabolic conditions.
Read the full article on GMJ Newsroom.
Was this article helpful?
